Fluzoparib with Temozolomide for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Jul 2025: Trial registered, NCT07047066

The trials

NCT07047066: A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma

State
Not started
Phase
Phase 2
People
30 planned
Started
10 Jul 2025
Primary completion
31 Jul 2026
Arms
Fluzoparib combined with Temozolomide
Results
None posted
  1. 2 Jul 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.